Arcellx, Inc. ACLX 深 沪
已收盘 04-28 16:00:00 美东时间
115.07
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 115.07
- 总市值 67.32亿
- 52周最高 115.13
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 53.07
- 委 比 0.00%
- 总股本 5850.63万
- 历史最高 115.13
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.035
- 每 手 1
- 风险率 18.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cantor Fitzgerald Suspends Neutral Rating on Arcellx
Cantor Fitzgerald suspends Neutral rating on Arcellx (NASDAQ:ACLX).
04-29 23:00
美股夜盘 | Intellia Therapeutics, Inc.涨29.42%，Organon & Co.涨15.36%
Intellia Therapeutics, Inc.涨29.42%；Organon & Co.涨15.36%；克里夫天然资源公司涨9.12%
04-27 15:01
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal
Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook.
04-08 00:06
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition
Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.
03-25 01:58
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX) and Atea Pharma (AVIR) among top-ranked.
03-18 20:59
Top 2 Health Care Stocks That May Crash This Quarter
2 stocks in healthcare sector flashing warning to investors who value momentum. RSI is an indicator that compares stock strength on up and down days.
03-04 21:55
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, March 3, 2026 /PRNewswire/ --The global oncology market is projected to nearly triple from $279.9...
03-03 22:00
财报速睇 | Arcellx, Inc. 2025财年年度营收0.22亿美元，同比下降79.4%；归母净利润亏损2.29亿美元，同比亏损扩大113.3%
华盛资讯2月27日讯，Arcellx, Inc.公布2025财年年度业绩，公司年度营收0.22亿美元，同比下降79.4%，归母净利润亏损2.29亿美元，同比亏损扩大113.3%。
02-27 13:09
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
